Related Experiment Video
Updated: May 6, 2026
Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
Published on: June 7, 2020
A Systematic Review and Meta-Analysis of Survival Prediction in Glioblastoma Patients Using Advanced MRI Techniques
Zayd Osama Jastaniah1, Mohammed Ahmed Alsubhi2, Yasser Noorelahi3
1Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University (Rabigh), Jeddah, Saudi Arabia.
Introduction:
Glioblastoma (GBM) is an aggressive brain tumor with a dismal prognosis. Recent advances in radiomics and machine learning (ML) applied to magnetic resonance imaging (MRI) have demonstrated promising potential in enhancing clinical decision-making and prognostic accuracy. This systematic review and meta-analysis aimed to evaluate the predictive performance of radiomics and ML techniques applied to pre-treatment MRI data in glioblastoma prognosis.
Methods:
A comprehensive literature search was conducted across MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials up to March 2024 for studies using radiomics or ML techniques applied to pre-treatment MRI scans to predict progression-free survival (PFS) and overall survival (OS) in glioblastoma patients. The primary outcome was the area under the receiver operating characteristic curve (AUC). Study quality was assessed using the QUADAS-2 tool, meta-analysis employed a random-effects model, and heterogeneity was evaluated using the I2 statistic.
Results:
Sixteen studies comprising a total of 2,342 patients were included. MRI-based machine learning models demonstrated high predictive performance for glioblastoma prognosis (AUC: 0.71-0.92), with a tendency to outperform radiomics-based approaches (AUC: 0.68-0.88). A meta-analysis of 12 studies yielded a pooled AUC of 0.78 (95% CI: 0.74-0.82; P < 0.001) for PFS prediction with moderate heterogeneity (I2 = 59%). Four studies focused on OS prediction, showing no heterogeneity (I2 = 0%) and a pooled AUC of 0.81 (95% CI: 0.77-0.85; P < 0.001). Subgroup analysis revealed that ML models (AUC: 0.83 [95% CI: 0.78-0.87]) statistically outperformed radiomics-based models (AUC: 0.76 [95% CI: 0.71-0.80]) for PFS prediction (P = 0.02).
Conclusion:
Radiomics and ML approaches based on pre-treatment MRI are promising tools for predicting survival outcomes in glioblastoma patients, with ML models demonstrating a slight edge over radiomics for PFS prediction. Standardized protocols and larger multi-center studies are warranted to facilitate clinical adoption.
